Last reviewed · How we verify
Mirikizumab Prefilled Syringe
At a glance
| Generic name | Mirikizumab Prefilled Syringe |
|---|---|
| Also known as | LY3074828 |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants (PHASE1)
- A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants (PHASE1)
- A Study of Injections of LY3074828 in Healthy Participants (PHASE1)
- A Study of LY3074828 in Healthy Participants (PHASE1)
- A Study of Mirikizumab in Healthy Participants (PHASE1)
- A Study of Two Different Formulations of LY3074828 in Healthy Participants (PHASE1)
- A Study of Two Formulations of LY3074828 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mirikizumab Prefilled Syringe CI brief — competitive landscape report
- Mirikizumab Prefilled Syringe updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI